JP2023506750A5 - - Google Patents

Info

Publication number
JP2023506750A5
JP2023506750A5 JP2022535429A JP2022535429A JP2023506750A5 JP 2023506750 A5 JP2023506750 A5 JP 2023506750A5 JP 2022535429 A JP2022535429 A JP 2022535429A JP 2022535429 A JP2022535429 A JP 2022535429A JP 2023506750 A5 JP2023506750 A5 JP 2023506750A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535429A
Other languages
English (en)
Japanese (ja)
Other versions
JP7837867B2 (ja
JP2023506750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/085623 external-priority patent/WO2021116337A1/en
Publication of JP2023506750A publication Critical patent/JP2023506750A/ja
Publication of JP2023506750A5 publication Critical patent/JP2023506750A5/ja
Priority to JP2025064328A priority Critical patent/JP2025111508A/ja
Application granted granted Critical
Publication of JP7837867B2 publication Critical patent/JP7837867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535429A 2019-12-11 2020-12-10 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用 Active JP7837867B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064328A JP2025111508A (ja) 2019-12-11 2025-04-09 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946452P 2019-12-11 2019-12-11
US62/946,452 2019-12-11
PCT/EP2020/085623 WO2021116337A1 (en) 2019-12-11 2020-12-10 Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064328A Division JP2025111508A (ja) 2019-12-11 2025-04-09 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用

Publications (3)

Publication Number Publication Date
JP2023506750A JP2023506750A (ja) 2023-02-20
JP2023506750A5 true JP2023506750A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7837867B2 JP7837867B2 (ja) 2026-03-31

Family

ID=74104042

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535429A Active JP7837867B2 (ja) 2019-12-11 2020-12-10 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用
JP2025064328A Pending JP2025111508A (ja) 2019-12-11 2025-04-09 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064328A Pending JP2025111508A (ja) 2019-12-11 2025-04-09 Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用

Country Status (9)

Country Link
US (2) US20210188990A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073111A1 (cg-RX-API-DMAC7.html)
JP (2) JP7837867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220130687A (cg-RX-API-DMAC7.html)
CN (1) CN115087670B (cg-RX-API-DMAC7.html)
AU (1) AU2020401755A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164226A1 (cg-RX-API-DMAC7.html)
IL (1) IL293742A (cg-RX-API-DMAC7.html)
WO (1) WO2021116337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115677851B (zh) * 2021-07-29 2024-03-22 东莞市朋志生物科技有限公司 一种免疫阻断抗体或其抗原结合片段及其应用
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) * 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
EP4551240A1 (en) 2022-07-08 2025-05-14 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
JP2026523881A (ja) 2023-07-07 2026-07-15 メスタッグ セラピューティクス エルティーディー 結合コンストラクト
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
IL328577A (en) 2023-11-24 2026-07-01 Medpacto Inc Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
CN100473664C (zh) 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
EP2825197B1 (en) 2012-03-16 2018-06-06 Covagen AG Novel binding molecules with antitumoral activity
HK1214605A1 (zh) 2013-04-19 2016-07-29 Covagen Ag 具有抗肿瘤活性的新颖的双特异性结合分子
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
JP6894430B2 (ja) * 2015-08-24 2021-06-30 セレクティスCellectis 統合された制御機能を有するキメラ抗原受容体
WO2018119118A1 (en) 2016-12-20 2018-06-28 Oncomed Pharmaceuticals, Inc. Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
TW202120537A (zh) * 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法

Similar Documents

Publication Publication Date Title
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2021529557A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2022191383A5 (cg-RX-API-DMAC7.html)
JP2024544520A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2022510964A5 (cg-RX-API-DMAC7.html)
JP2024531409A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2020537520A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2025016538A5 (cg-RX-API-DMAC7.html)
JP2022534135A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2023516195A5 (cg-RX-API-DMAC7.html)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)